Establishment of an Evaluation Method for Gene Silencing by Serial Pulmonary Administration of siRNA and pDNA Powders: Naked siRNA Inhalation Powder Suppresses Luciferase Gene Expression in the Lung
- 4 April 2019
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (8) , 2661-2667
Abstract
No abstract availableKeywords
Funding Information
- Nagai Memorial Research Scholarship (N-173901)
This publication has 20 references indexed in Scilit:
- Gene-silencing technology gets first drug approval after 20-year waitNature, 2018
- Naked pDNA Inhalation Powder Composed of Hyaluronic Acid Exhibits High Gene Expression in the LungsMolecular Pharmaceutics, 2018
- Development of spray-freeze-dried siRNA/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activityJournal of Controlled Release, 2018
- Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancerInternational Journal of Pharmaceutics, 2017
- FDA-Approved Oligonucleotide Therapies in 2017Molecular Therapy, 2017
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering DrugsNew England Journal of Medicine, 2017
- Gene Silencing in a Mouse Lung Metastasis Model by an Inhalable Dry Small Interfering RNA Powder Prepared Using the Supercritical Carbon Dioxide TechniqueBiological and Pharmaceutical Bulletin, 2013
- Pioneering gene therapy on brink of approvalNature Reviews Drug Discovery, 2012
- Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003
- Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegansNature, 1998